Marsh McLennan Agency’s webinar on GLP-1 drugs is featured in HR Drive
GLP-1 agonists, used for managing type 2 diabetes and promoting weight loss, are experiencing growing interest among businesses. However, new trends bring new questions. How effective are these drugs? And what do employers need to consider before adding them to their formulary?
HR Dive covered Marsh McLennan Agency’s recent panel webinar about some of the important decisions employers must make regarding introducing drugs like Ozempic and Wegovy. Hosted by Kate Moher, President and National Practice Leader of Employee Health & Benefits at Marsh Mclennan Agency, panelists discussed the pros and cons of GLP-1s from an employer’s perspective and best practices for adding them to their formulary.
“It’s really important that there’s an independent assessment of what is the proper authorization assessment for the PBM to make sure they’re really only allowing the Type 2 diabetics to get that medication,” said Rick Kelly, National Pharmacy Practice Leader at Marsh McLennan Agency.
